Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
7/23/2007
 
First Published:
11/24/2002
1.
Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40-Ligand Treatment in Patients With HLA-A1 and/or HLA-A2.1 Positive Stage III or IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
Over 18
Other
ERLANGEN-1490
EU-20232, NCT00053391
Last Modified:
6/27/2006
 
First Published:
8/1/2000
2.
Phase II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides From MART-1:26-35, gp100:209-217, and Tyrosinase:368-372 and Treated Ex Vivo With CD40-Ligand and Interferon Gamma, Followed By Interleukin-2 In Vivo in HLA-A2.1 Positive Patients With Stage III or IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
LAC-USC-10M991
NCI-G00-1837, NCI-T99-0102, NCT00006113, T99-0102
Last Modified:
11/1/1999
 
First Published:
10/1/1998
3.
Phase I Study of CD40-Ligand (CD154) Gene-Transduced Leukemia Cells in Patients with Chronic Lymphocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
Over 21
NCI
UCSD-970976
NCI-G98-1477
Last Modified:
4/1/2002
 
First Published:
5/1/2001
4.
Phase I Study of CD40-Ligand and Flt3 Ligand in Patients With Metastatic Melanoma or Renal Cell Cancer (Summary Last Modified 04/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
16 and over
NCI
NCI-01-C-0121
NCI-1035, NCT00020540, 1035
5.
Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine.
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
75 and under
Other
H6408
NCT00058799
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute